Haipeng Xu

机构：Zhejiang Chinese Medical University, Shandong University of Technology, Fujian Medical University, Nanjing Forestry University, Wenzhou Medical University, Shanghai University of Traditional Chinese Medicine, Northeast Institute of Geography and Agroecology, Cube Technology (United States), Zhejiang Lab, Shanghai Traditional Chinese Medicine Hospital, Jinzhou Kangning Hospital, Fujian Provincial Cancer Hospital, First Affiliated Hospital Zhejiang University, Chaohu University · ORCID：0000-0001-7511-4991

发表论文 70 篇 · 总被引 1207 次 · h-index 18

代表论文

• Exploring the relationship between lignin structure and antioxidant property using lignin model compounds (2024 · International Journal of Biological Macromolecules · 被引 49)
• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 33)
• Supply and demand of agricultural water resources under future saline-alkali land improvement (2025 · Agricultural Water Management · 被引 18)
• Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET -amplification ( MET amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study. (2025 · Journal of Clinical Oncology · 被引 9)
• Unraveling the Structure–Antioxidant Property Relationship of Lignin: Insights from Botanical Sources and pH-Controlled Fractionation (2025 · Biomacromolecules · 被引 7)
• Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors. (2025 · Journal of Clinical Oncology · 被引 6)